BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29950348)

  • 1. Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease-Associated Colorectal Cancers.
    Din S; Wong K; Mueller MF; Oniscu A; Hewinson J; Black CJ; Miller ML; Jiménez-Sánchez A; Rabbie R; Rashid M; Satsangi J; Adams DJ; Arends MJ
    Clin Cancer Res; 2018 Oct; 24(20):5133-5142. PubMed ID: 29950348
    [No Abstract]   [Full Text] [Related]  

  • 2. Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers.
    Robles AI; Traverso G; Zhang M; Roberts NJ; Khan MA; Joseph C; Lauwers GY; Selaru FM; Popoli M; Pittman ME; Ke X; Hruban RH; Meltzer SJ; Kinzler KW; Vogelstein B; Harris CC; Papadopoulos N
    Gastroenterology; 2016 Apr; 150(4):931-43. PubMed ID: 26764183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability.
    Svrcek M; El-Bchiri J; Chalastanis A; Capel E; Dumont S; Buhard O; Oliveira C; Seruca R; Bossard C; Mosnier JF; Berger F; Leteurtre E; Lavergne-Slove A; Chenard MP; Hamelin R; Cosnes J; Beaugerie L; Tiret E; Duval A; Fléjou JF
    J Clin Oncol; 2007 Sep; 25(27):4231-8. PubMed ID: 17878476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.
    Donehower LA; Creighton CJ; Schultz N; Shinbrot E; Chang K; Gunaratne PH; Muzny D; Sander C; Hamilton SR; Gibbs RA; Wheeler D
    J Pathol; 2013 Jan; 229(1):99-110. PubMed ID: 22899370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases.
    Svrcek M; El-Murr N; Wanherdrick K; Dumont S; Beaugerie L; Cosnes J; Colombel JF; Tiret E; Fléjou JF; Lesuffleur T; Duval A
    Carcinogenesis; 2013 Apr; 34(4):828-34. PubMed ID: 23288924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers.
    Olaru AV; Cheng Y; Agarwal R; Yang J; David S; Abraham JM; Yu W; Kwon JH; Lazarev M; Brant SR; Marohn MR; Hutcheon DF; Harpaz N; Meltzer SJ; Mori Y
    Inflamm Bowel Dis; 2012 Apr; 18(4):641-8. PubMed ID: 21830278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.
    Lee M; Eng G; Barbari SR; Deshpande V; Shcherbakova PV; Gala MK
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00149. PubMed ID: 32352724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer.
    Rajamäki K; Taira A; Katainen R; Välimäki N; Kuosmanen A; Plaketti RM; Seppälä TT; Ahtiainen M; Wirta EV; Vartiainen E; Sulo P; Ravantti J; Lehtipuro S; Granberg KJ; Nykter M; Tanskanen T; Ristimäki A; Koskensalo S; Renkonen-Sinisalo L; Lepistö A; Böhm J; Taipale J; Mecklin JP; Aavikko M; Palin K; Aaltonen LA
    Gastroenterology; 2021 Aug; 161(2):592-607. PubMed ID: 33930428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers.
    Alpert L; Yassan L; Poon R; Kadri S; Niu N; Patil SA; Mujacic I; Montes D; Galbo F; Wurst MN; Zhen CJ; Cohen RD; Rubin DT; Pekow JR; Weber CR; Xiao SY; Hart J; Segal J; Setia N
    Hum Pathol; 2019 Jul; 89():44-50. PubMed ID: 31054900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
    Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
    Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
    Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL
    BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
    de Krijger M; Carvalho B; Rausch C; Bolijn AS; Delis-van Diemen PM; Tijssen M; van Engeland M; Mostafavi N; Bogie RMM; Dekker E; Masclee AAM; Verheij J; Meijer GA; Ponsioen CY
    Inflamm Bowel Dis; 2022 Sep; 28(9):1309-1320. PubMed ID: 35554535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational profiling of colorectal cancers with microsatellite instability.
    Lin EI; Tseng LH; Gocke CD; Reil S; Le DT; Azad NS; Eshleman JR
    Oncotarget; 2015 Dec; 6(39):42334-44. PubMed ID: 26517354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability.
    Jonchere V; Marisa L; Greene M; Virouleau A; Buhard O; Bertrand R; Svrcek M; Cervera P; Goloudina A; Guillerm E; Coulet F; Landman S; Ratovomanana T; Job S; Ayadi M; Elarouci N; Armenoult L; Merabtene F; Dumont S; Parc Y; Lefèvre JH; André T; Fléjou JF; Guilloux A; Collura A; de Reyniès A; Duval A
    Cell Mol Gastroenterol Hepatol; 2018; 6(3):277-300. PubMed ID: 30116770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of Genome Alterations in Crohn's Disease-Associated Colorectal Carcinogenesis.
    Hirsch D; Wangsa D; Zhu YJ; Hu Y; Edelman DC; Meltzer PS; Heselmeyer-Haddad K; Ott C; Kienle P; Galata C; Horisberger K; Ried T; Gaiser T
    Clin Cancer Res; 2018 Oct; 24(20):4997-5011. PubMed ID: 29967250
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer.
    Jin HY; Liu X; Li VK; Ding Y; Yang B; Geng J; Lai R; Ding S; Ni M; Zhao R
    BMC Cancer; 2008 Feb; 8():44. PubMed ID: 18257912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.
    Carethers JM; Jung BH
    Gastroenterology; 2015 Oct; 149(5):1177-1190.e3. PubMed ID: 26216840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
    Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
    Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers.
    Georgeson P; Pope BJ; Rosty C; Clendenning M; Mahmood K; Joo JE; Walker R; Hutchinson RA; Preston S; Como J; Joseland S; Win AK; Macrae FA; Hopper JL; Mouradov D; Gibbs P; Sieber OM; O'Sullivan DE; Brenner DR; Gallinger S; Jenkins MA; Winship IM; Buchanan DD
    Gut; 2021 Nov; 70(11):2138-2149. PubMed ID: 33414168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.